Rising incidences of meningococcal disease has considerably encouraged the development of vaccines targeting wide range of serogroups of meningococci. The highest incidence meningitis is found in the ‘meningitis belt’ of the sub-Saharan African region. For instance, in this region, major epidemics occur every 5 to 12 years, i.e. an attack rate of around 1,000 cases per 100,000 population. Global health organizations, private sector companies and government bodies across several regions are continuously promoting active immunization campaigns against meningococcal diseases. For instance, in May 2018, “Defeating meningitis by 2030” was introduced at the World Health Assembly, which aims at eradicating meningitis from all high-risk countries by 2030.
The Meningococcal Vaccines Market is segmented on the basis of Vaccine Types, Patient Type and region.
Major Vaccine Types of Meningococcal Vaccines Market covered are:
- Polysaccharide-Based Vaccines
- Quadrivalent Conjugate Vaccines
- Serogroup B Vaccines
- Others
Major Patient Types of Meningococcal Vaccines Market covered are:
- Pediatric Patients
- Adult Patients
- Others
Extensive research by key players for development of novel vaccine targeting difficult serogroups such as serogroup B of meningococci further contributes in the growth of the market. For instance, In February 2018, Bexsero developed by GlaxoSmithKline plc received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). Bexsero is a vaccine which is meant for prevention of Invasive Meningococcal Disease (IMD) caused by serogroup B among children aged between 2 to 10 years.
No comments:
Post a Comment